Orbital Therapeutics, a biotechnology company pioneering a new generation of RNA medicines that reprogramme the immune system in vivo to treat disease at its source, have appointed Adam Raff, as Senior Vice President, Clinical Development. Raff will oversee Orbital’s clinical and regulatory strategy and execution and will serve as a key member of the company’s executive leadership team.
“Adam brings exceptional depth of experience in translating innovative science into impactful therapeutics, with a proven track record of successfully leading clinical development programs from discovery through pivotal trials,” said Ron Philip, Chief Executive Officer at Orbital. “His expertise in immunology and inflammatory diseases, combined with his unique background as a practicing physician-scientist and drug developer, makes him ideally suited to advance Orbital’s diverse RNA medicine portfolio. Adam joins at just the right time, as we progress OTX-201 through IND-enabling studies following encouraging preclinical data, with clinical development expected to begin in the first half of 2026.”
Raff brings over a decade of experience in drug development and clinical research, spanning early discovery through late-stage clinical development, with extensive expertise in immunology and inflammatory disorders. He previously held leadership roles at Montai Therapeutics, EQRx (acquired by Revolution Medicines in 2023) and LEO Pharma.
Raff said: “Orbital’s mission to develop a new generation of in vivo RNA medicines represents an extraordinary opportunity to transform how we treat human disease. “The company’s first-in-kind platform at the intersection of RNA technology, delivery methods and AI-guided design has tremendous potential to address unmet medical needs across multiple therapeutic areas. I’m excited to join this talented team and help translate Orbital’s innovative science into life-changing therapies for patients.”